BioCentury
ARTICLE | Company News

Vertex’s CF ‘firepower’ to fund more deals, broader pipeline

August 1, 2019 12:00 AM UTC

Vertex unveiled a series of new programs Wednesday and provided a glimpse of how it plans to use the cash from its cystic fibrosis portfolio to fuel deals that will continue to propel the company into pain and rare diseases.

As Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) prepares for a potential 2020 launch of its triple combination CF therapy that can treat up to 90% of patients, Jeffrey Leiden will step down as president and CEO and become executive chairman in April (see "As Vertex Broadens Remit, Leiden Handing Baton to Kewalramani")...

BCIQ Company Profiles

Vertex Pharmaceuticals Inc.